|
Henry I. Miller is an American medical researcher and columnist, formerly with the FDA, since 1994 the Robert Wesson Fellow in Scientific Philosophy and Public Policy at Stanford University's Hoover Institution, a public policy think tank located on the university's campus in California. He is an Adjunct Fellow of the Competitive Enterprise Institute. ==Career== Miller was born on July 1, 1947 in South Philadelphia and raised there. He was educated at M.I.T. (B.S. in Life Sciences) and the University of California, San Diego (M.Sc. and M.D.) and was a resident and Clinical Fellow in Medicine at Harvard's Beth Israel Hospital in Boston. He performed research on gene organization and expression as a Research Fellow in the laboratory of Philip Leder M.D. at the National Institutes of Health. Miller was a civil servant for fifteen years at the US Food and Drug Administration (FDA) (1979–94). He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and was instrumental in the rapid licensing of genetically engineered human insulin and human growth hormone. From 1985 to 1989, he was a special assistant to the FDA commissioner and from 1989 to 1993, the founding director of the FDA's Office of Biotechnology. Since coming to the Hoover Institution in 1994, Miller has authored books and articles in scholarly journals, newspapers and online. He has been an Adjunct Fellow at the Competitive Enterprise Institute. He also has been a director of American Council on Science and Health and a Consulting Professor at Stanford University's Institute for International Studies (now the Freeman Spogli Institute for International Studies). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Henry I. Miller」の詳細全文を読む スポンサード リンク
|